Planar Lymphoscintigraphy for sentinel lymph node mapping in dogs with mast cell tumor: a pilot study.
PDF (English)

File supplementari

Untitled (English)

Parole chiave

Sentinel Lymph Node
Mast Cell Tumor
Lymphoscintigraphy
Diagnostic Imaging
Oncology

Abstract

The histopathological assessment of the first node receiving lymphatic drainage from a tumor – defined as Sentinel Lymph Node (SLN) – is essential to determine stage, therapy and outcome in oncological patients. Both in human and veterinary medicine, lymphoscintigraphy is a recognized procedure for SLN detection (Mariani et al., 2004; Tuohy et al., 2009; Beer et al., 2017). In this study, we want to determine the most suitable pre-operative planar lymphoscintigraphy protocol for SLN mapping in dogs with mast cell tumor (MCT). We selected 5 dogs diagnosed with cutaneous MTC, with clinically negative lymph nodes and no distant metastasis, undergoing surgical tumor removal, and we obtained owner’s written consent. Planar lymphoscintigraphy was performed in patients under general anesthesia, after subcutaneous peritumoral injection of different doses of technetium-99m (Tc-99m) labelled colloid diluted reaching a 0.5 ml volume (Worley, 2014). The MegaBecquerel value (MBq) of the syringe was measured before and after the injection. Dynamic images (1 frame/second for 60 seconds) were taken at the moment of the injection, 3 and 8 minutes after the injection. Ventrodorsal (VD) and lateral (L) static images (120 seconds/frame) were taken until the identification of SLN had been made. If needed, the injection site was masked with a 2-mm lead foil. Results are showed in Table 1. In patient 1, the SLN was not identify, probably due to a superimposition with the injection site. During the study, we increased the injected MBq dose, in order to better visualize lymphatic path and SLN (Balogh et al., 2002). In fact, the number of static images needed to identify SLN have been reduced from 8,7 to 6. Masking the injection site proved to be useful for a better visualization of SLN. Dynamic images showed to be unnecessary for the SLN identification. For further studies, we suggest the injection of minimum 23,5 MBq Tc-99m activity and the acquisition of VD and L static images with and without masking the injection site.

https://doi.org/10.13130/2283-3927/10022
PDF (English)

Riferimenti bibliografici

Balogh, L., Thuroczy, J., Andocs, G., Mathé, D., Chaudhari, P., Perge, E., Biksi, I., Polyák, A., Király, R., Jánoki, G., A., 2002. Sentinel lymph node detection in canine oncological patients. Nuclear Medicine Review. 5(2), 139-144.

Beer, P., Pozzi, A., Rohrer Bley, C., Bacon, N., Pfammatter, N., S., Venzin, C., 2018. The role of sentinel lymph node mapping in small animal veterinary medicine: A comparison with current approaches in human medicine. Veterinary and Comparative Oncology. 16(2), 178-187.

Mariani, G., Erba, P., Villa, G., Gipponi, M., Manca, G., Boni, G., Buffoni, F., Castagnola, F., Paganelli, G., Strauss, H., W., 2004. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective. Journal of Surgical Oncology. 85(3), 112-122.

Tuohy, J., L., Milgram, J., Worley, D., R., Dernell, W., S., 2009. A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology. Veterinary and Comparative Oncology. 7(2), 81-91.

Worley, D., R., 2014. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Veterinary and Comparative Oncology. 12(3), 215-226.

This work is licensed under a CC BY-SA 4.0 international